Related Experiment Video

Updated: Jun 9, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src

Tomoya Hikita1, Chitose Oneyama, Masato Okada

  • 1Department of Oncogene Research, Research Institute of Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan.

Genes to Cells : Devoted to Molecular & Cellular Mechanisms
|September 10, 2010
PubMed

Insights

Purvalanol A, a CDK inhibitor, effectively suppresses cancer growth driven by c-Src. It inhibits both cell cycle progression and tyrosine kinase signaling, showing promise as an anticancer agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The nonreceptor tyrosine kinase c-Src is often over-expressed in human cancers, promoting tumor progression.
  • Current Src-selective anticancer drugs are still under clinical investigation, necessitating the search for novel therapeutic strategies.

Purpose of the Study:

  • To develop a novel screening platform to identify effective inhibitors of c-Src-mediated cancer progression.
  • To evaluate the efficacy of purvalanol A, a known CDK inhibitor, as a potential anticancer agent targeting c-Src.

Main Methods:

  • Utilized Csk-deficient cells transformable by c-Src for a new screening platform.
  • Assessed purvalanol A's effects on anchorage-independent growth, c-Src activity, cell morphology, cell cycle progression, and cancer cell growth (HT29, SW480).
  • Compared purvalanol A's efficacy and cytotoxicity with the Src-selective inhibitor PP2.

Main Results:

  • Purvalanol A potently suppressed anchorage-independent growth of c-Src-transformed cells, indicating CDK involvement in c-Src transformation.
  • Purvalanol A inhibited c-Src activity comparable to PP2 but with reduced cytotoxicity and reversion of transformed morphology.
  • Purvalanol A induced G2-M arrest, while PP2 primarily affected G1-S transition.
  • Purvalanol A demonstrated superior suppression of colon cancer cell growth (HT29, SW480) compared to PP2.

Conclusions:

  • Purvalanol A's multi-selective inhibition of cell cycle progression and tyrosine kinase signaling is effective against c-Src-driven cancers.
  • Purvalanol A represents a promising therapeutic candidate for cancers associated with c-Src over-expression and activation.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.